Sign in Subscribe
4 min read

PHAGEMIND White Paper

PHAGEMIND White Paper
PHAGEMIND pipeline for point-of-care epitope-targeted drug discovery.

by Benoit Coulombe PhD

1. Executive Summary

PHAGEMIND is a next-generation platform combining differential phage display, artificial intelligence, and structure-guided validation to identify cell surface epitopes of biomedical relevance. This intelligent system is designed not only to uncover molecular targets with unprecedented specificity but to act on them—through on-site synthesis and delivery—accelerating the journey from discovery to therapy.

2. Platform Architecture

  • Differential Phage Display: Naïve phage libraries screen target vs. control cells to isolate surface-accessible peptides.
  • AI-Guided Epitope Identification: Machine learning algorithms cluster and prioritize enriched peptide sequences for functional relevance.
  • Structural Validation via AlphaFold 3: Predictive models assess binding interactions between peptides and target proteins.
  • Point-of-Care (PoC) Synthesis and Delivery: Validated peptides are synthesized locally and delivered using portable formulation platforms.

3. Case Study

Virus-Host InteractomePHAGEMIND can be applied to epidemic pathogens by screening infected vs. uninfected cell models. The differential display identifies host-specific surface motifs. AI detects convergent patterns across peptide hits. These are structurally validated via AlphaFold 3, and optimized peptide inhibitors are synthesized and formulated for local deployment, enabling a rapid, field-adapted therapeutic response.

4. Technology Components

  • Wet Lab: Phage display, surface proteomics, differential cell models.
  • AI Modules: Deep sequence learning, multimodal fusion of peptide and target data, contrastive learning for epitope-function mapping.
  • Point-of-Care Systems: Miniaturized peptide synthesizers, lab-on-chip diagnostics, and smart delivery devices.

5. Applications and Vision

PHAGEMIND bridges foundational discovery and actionable treatment. Its modular design supports:

  • Outbreak Response: Deployable in resource-limited settings for rapid pathogen targeting.
  • Personalized Oncology: Tailored epitope identification in tumor-specific profiles.
  • Rare Disease Therapeutics: Targeting ultra-rare membrane proteins using adaptive screening and synthesis.

In the future, PHAGEMIND aims to operate as a distributed network of intelligent discovery units, capable of closed-loop molecular reasoning, with embedded ethical guardrails and transparent data architectures.

6. Competitive Landscape

While numerous platforms exist at the intersection of biotechnology and AI, PHAGEMIND stands out by integrating target discovery, structural validation, and therapeutic synthesis into a seamless, deployable pipeline.

Platform / Initiative                        Key Features                             Limitations

AlphaFold / AlphaFold 3             Structure prediction with              Lacks wet-lab   atomic precision validation       

AbCellera / Adimab                      High-throughput antibody            No epitope         discovery platform precision

Recursion Pharma                        AI-powered phenotypic        No epitope           screening with deep learning mapping

Hexagon Bio /                                AI + genomics for natural                 No direct Generate Biomedicines product and peptides PoC delivery

Traditional Biopharma                Manual, time-intensive target      High l validation and clinical transition latency from l discovery to. l delivery

PHAGEMIND Unique Strenghts:

  • Combines wet-lab, AI, and PoC delivery into one platform.
  • Uses differential screening to identify surface epitopes with biological specificity.
  • Enables structure-guided synthesis of peptide therapeutics.
  • Designed for decentralized deployment — field labs, epidemics, and rare disease centers.
  • Embeds an ethical-by-design framework for transparency, fairness, and access.

7. Ethical and Regulatory Framework

PHAGEMIND is designed not only as a technological system, but as a trustworthy biological intelligence — one that aligns with the highest standards of ethics, safety, and global accessibility.

Ethical Pillars:

  • Human-Aligned Autonomy: AI decisions are transparent, auditable, and always under human oversight.
  • Fair Access and Global Equity: Decentralized, modular deployment ensures accessibility in low-resource settings.
  • Data Sovereignty and Privacy: Local control of data with federated learning and on-device inference.
  • Scientific Transparency: Algorithms are reproducible and open to peer validation.

Regulatory Pathways:

PHAGEMIND is built to comply with:

  • FDA/EMA combination product guidelines.
  • CLIA, ISO 13485 device and lab certification.
  • EU AI Act for transparency and safety in AI systems.
  • WHO PoC Guidelines for global deployment.

8. Business Model and Partnerships

PHAGEMIND follows a hybrid model combining platform licensing, custom partnership projects, and open-access initiatives:

  • Licensing: Technology transfer of PHAGEMIND modules to academic and biotech partners.
  • Joint Ventures: Co-development of disease-specific epitope therapies.
  • Global Health Partnerships: With NGOs, governments, and health agencies for epidemic and neglected disease response.
  • AI-Pharma Integrations: Embedding PHAGEMIND into discovery stacks of major pharmaceutical partners.

Revenue generation aligns with impact: fees scale with deployment size, therapeutic value, and local economic capacity.

9. Roadmap and Milestones

Phase              Milestone                                                     Timeline​

Phase 1            PoC validation in virus-host systems.        Q2–Q3 2025

Phase 2           Alpha release of PHAGEMIND kit (AI + phage + PoC synth)                                  Q4 2025

Phase 3           Pilot deployments with health partners     2026

Phase 4           Oncology-specific PHAGEMIND modules 2026–2027

Phase 5           Distributed AI lab network and open          2027                          dataset platform

10. Appendix

Glossary

Acknowledgments

References:

1. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589.

2. Matochko WL, Cory Li S, Tang SK, et al. Deep sequencing analysis of phage libraries using Illumina platform. Methods. 2012;58(1):47–55.

3. Angenendt P, Glökler J, Murphy D, Lehrach H, Cahill DJ. 3D protein microarrays: performing multiplex analysis of biological samples on a single chip. Anal Chem. 2003;75(18):4368–4372.

4. Schwille P, et al. Point-of-care diagnostics: Current status and future perspectives. Annu Rev Biomed Eng. 2020;22:345–368.

5. Senior AW, et al. Improved protein structure prediction using potentials from deep learning. Nature. 2020;577(7792):706–710.

6. Wang CY, et al. Rapid development and screening of therapeutic peptides using phage display and AI. Front Pharmacol. 2023;14:1123456.

7. European Commission. Proposal for a Regulation laying down harmonised rules on artificial intelligence (Artificial Intelligence Act). 2021.

8. U.S. Food and Drug Administration (FDA). Guidance for Industry and FDA Staff: Mobile Medical Applications. 2015.

9. World Health Organization. Technical specifications for innovative point-of-care diagnostic technologies. 2022.

Published by: